Category: ACN Newswire

RESULTS HIGHLIGHTS:- The Revenue for the six months ended 30 June 2025 (“the Period”) was approximately HK$1,834.8 million, representing an increase of approximately 7.8% as compared with the same period last year. The increase in the revenue was mainly due to the continued organic growth of the Group (mainly in Europe and Australia regions) and accelerated by our acquisition of Hexa Ceram Company Limited (“Hexa Ceram”), Thailand’s largest dental laboratory, which was completed in January 2025.- The Gross Profit Margin for the six months ended 30 June 2025 was approximately 54.8%; the gross profit was approximately HK$1,005.5 million, representing an increase of approximately 10.0% as compared with the same period last year.- The Group’s EBITDA for the six months ended 30 June 2025 was approximately HK$456.7 million, representing an increase of approximately 21.6% as compared with the same period last year.- The Group’s Net Profit for the six months ended 30 June 2025 was approximately HK$288.7 million, representing an increase of approximately 34.7% as compared with the same period last year.- Basic earnings per share for the six months ended 30 June 2025 amounted to HK30.37 cents.- The Board declared an interim dividend of HK10.7 cents per ordinary share for the six months ended 30 June 2025.- For the six months ended 30 June 2025, the Group’s digital solution cases (overseas and domestic) that are produced from its Mainland China, Thailand and Vietnam production facilities increased to approximately 457,653 cases, reflecting an increase of 24.4% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - 28 August, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, is pleased to announce the unaudited interim results for the six months ended 30 June 2025.During the six months ended 30 June 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. By leveraging on our sales and distribution network, we achieved a leading position in the dental prosthetics industry across Europe, North America, Greater China, Australia, and other countries.European BusinessesThe revenue generated from sales in the European markets accounted for the largest portion of our revenue for the period under review. During the period, the European market recorded a revenue of approximately HK$920.3 million, representing an increase of approximately HK$97.3 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 50.2% of the Group’s total revenue. The increase in revenue from the European market was attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the front runner providing comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed to and will continue to equip ourselves to provide the state-of-the-art digital solutions offering to the dental community in the market.North American BusinessesThe North American market represented the second largest portion of our revenue in the period under review. During the period, the North American market recorded a revenue of approximately HK$365.7 million, representing a decrease of approximately HK$19.6 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 19.9% of the Group’s total revenue.While demand for discretionary cosmetic treatments remained soft throughout the first half of 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers. Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties - an advantage that sets us apart from competitors. Although digitalization of imported product lines initially drove growth in mass-market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a subsequent decline in sales for our import-focused business unit.Greater China BusinessesDuring the period under review, the Greater China market recorded a revenue of approximately HK$293.2 million, representing a decrease of approximately HK$42.6 million as compared with six months ended 30 June 2024. This geographic market accounted for approximately 16.0% of the Group’s total revenue. The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesDuring the period under review, the Australian market recorded a revenue of approximately HK$137.9 million, representing an increase of approximately HK$10.0 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 7.5% of the Group’s total revenue. The double-digit increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 4.0% compared with the six months ended 30 June 2024.Other MarketsOther markets primarily include Indian Ocean countries, Malaysia, Taiwan, Singapore and Thailand. For the six months ended 30 June 2025, these markets recorded a revenue of approximately HK$117.8 million, representing an increase of approximately HK$87.9 million as compared with the six months ended 30 June 2024. This geographic market accounted for approximately 6.4% of the Group’s total revenue. The increase in revenue from other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical challenges creating headwinds for businesses worldwide. However, the Group’s well-diversified global presence, spanning multiple regions and markets, positions it uniquely to navigate these challenges. Unlike competitors who operate in single countries or limited regions, the Group’s balanced and diversified country risk strategy ensures resilience and stability, even in turbulent times. This global footprint, combined with our ability to adapt to local market conditions, places the Group in the best position to outperform competitors and capitalize on emerging opportunities.Digitalization is an irreversible trend driving the consolidation of the dental prosthetics industry. The Group is taking full advantage of this trend, leveraging its centralized digital workflows, advanced production capabilities, and global network to enhance operational efficiencies and deliver superior customer experiences. Our continued investment in digitalization not only strengthens our competitive edge but also accelerates the consolidation of the industry, enabling the Group to capture a larger market share.Following our landmark acquisitions in previous years, including the recent acquisition of Hexa Ceram, Thailand’s largest dental laboratory, in January 2025, the Group’s global distribution and sales network is further diversified with a larger presence in Southeast Asia region. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides the Group with unparalleled flexibility to navigate challenges in connection with trade uncertainties and other geopolitical risks. With the Board’s extensive experience and determination to overcome short-term challenges, the Group is well-positioned to seize new business opportunities while remaining cautious and prudent in safeguarding shareholders’ interests.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 30,000 customers. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年6月30日止六個月(「回顧期」)的收益約為18.3億港元，較去年同期增加約7.8%。收益增加主要由於本集團持續的自然增長(主要在歐洲及澳洲地區)，並藉著我們於2025年1月完成收購泰國最大的牙科實驗室Hexa Ceram Company Limited(「Hexa Ceram」)而加快。- 截至2025年6月30日止六個月的毛利率約為54.8%；毛利約為10.1億港元，較去年同期增加約10.0%。- 本集團於截至2025年6月30日止六個月的EBITDA約為4.6億港元，較去年同期增加約21.6%。- 本集團截至2025年6月30日止六個月的純利約為2.9億港元，較去年同期增加約34.7%。- 截至2025年6月30日止六個月的每股基本盈利為30.37港仙。- 董事會已宣派截至2025年6月30日止六個月的中期股息每股普通股10.7港仙。- 截至2025年6月30日止六個月，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案(海外及國內)增加至約457,653件，較2024年同期增加24.4%，原因為客戶持續採用口腔內部掃描儀。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 8月28日， 全球領先之義齒器材供應商-現代牙科集團有限公司（簡稱「現代牙科」或「本集團」，股份代號：03600.HK）欣然公佈截至2025年6月30日止6個月之未經審核中期業績。截至2025年6月30日止六個月，在牙科行業數碼化趨勢的持續支持下，本集團的多維度策略及持續提升的營運效率及生產力使其於本期間的收益、純利及EBITDA均創下紀錄。此情況在宏觀經濟環境充滿挑戰之時，包括牙科手術的需求普遍疲弱及貿易戰的不確定性下仍能體現。本集團充分善用位於泰國、越南及中國內地的全球化生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動整合義齒行業，讓本集團進一步增加其於業內的市場份額。而我們數碼化的持續轉型有望改善顧客及患者的體驗，可令本集團在競爭對手中脫穎而出，表現優於同行。憑藉銷售及經銷網絡的優勢，我們於歐洲、北美、大中華、澳洲及其他國家的義齒行業均取得領先地位。歐洲市場業務自歐洲市場的銷售收益佔我們於回顧期間收益的最大部分。於回顧期間，歐洲市場錄得收益約9.2億港元，較截至2024年6月30日止六個月增加約9,734.1萬港元。此地理市場佔本集團收益總額約50.2%。歐洲市場收益增加是由於推出新產品(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過建立以教育及數碼化為重點且貼近客戶需求的牙科解決方案生態系統，積極從國際及本地競爭對手取得市場份額；並透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務自北美市場的銷售收益佔回顧期間收益的第二大部分。於回顧期間，北美市場錄得收益約3.7億港元，較截至2024年6月30日止六個月減少約1,964.5萬港元。此地理市場佔本集團收益總額約19.9%。雖然2025年上半年對主動美容治療的需求仍然疲弱，我們的中央化數碼流程及廣泛的生產網絡讓我們為北美客戶提供更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，在應對美國關稅的不確定性時帶來更大的彈性 - 使我們比其他競爭對手更具優勢。雖然進口產品線的數碼化起初帶動整體市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的後續銷售帶來下跌。大中華市場業務於回顧期間，大中華市場錄得收益約2.9億港元，較截至2024年6月30日止六個月減少約4,257.6萬港元。此地理市場佔本集團收益總額約16.0%。中國內地市場面對帶量採購政策及持續價格競爭的逆境。此亦導致中國內地診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意轉移低利潤業務，並專注於服務中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，促進公平競爭；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其規模化的生產團隊中得益及根據顧客或客戶更有效分配資源。澳洲市場業務於回顧期間，澳洲市場錄得收益約1.4億港元，較截至2024年6月30日止六個月增加約995.6萬港元。此地理市場佔本集團收益總額約7.5%。澳洲的收益錄得雙位數增長，反映牙科行業數化碼趨勢帶動更多新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年6月30日止六個月，澳元兌港元貶值4.0%抵銷所致。其他市場其他市場主要包括印度洋國家、馬來西亞、台灣、新加坡及泰國。截至2025年6月30日止六個月，該等市場錄得收益約1.2億港元，較截至2024年6月30日止六個月增加約8,790.7萬港元。此地理市場佔本集團收益總額約6.4%。其他市場的收益增加主要由於新收購的Hexa Ceram的收益貢獻所致。展望及策略全球宏觀經濟環境仍然不明朗，地緣政治挑戰讓全球各行業處於逆境當中。然而，本集團的業務遍及全球多個地區及市場，多元化的經營使其在面對該等挑戰時享有獨特優勢。有別於在單一國家或有限地區經營的競爭對手，本集團均衡多元的國家風險策略，確保其在動盪時刻仍然堅毅不屈，平穩過渡。憑藉全球佈局及我們適應當地市場環境的能力，使本集團的表現優於競爭對手，並能把握新興機遇。數碼化勢不可擋，帶動義齒行業的整合。本集團於此趨勢中盡享優勢，憑藉其中央化數碼工作流程、先進的生產能力及全球化網絡，旨在提升營運效率及提供卓越的客戶體驗。我們持續對數碼化的投資不僅加強我們的競爭優勢，亦加快行業的整合，本集團可以從中獲得更大的市場份額。我們在過往多年作出多項標誌性收購，包括最近於2025年1月收購泰國最大牙科實驗室Hexa Ceram，本集團的全球分銷及銷售網絡進一步多元化，加強在東南亞地區的影響力。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓本集團在應對與貿易不明朗因素及其他地緣政治風險等相關的挑戰時帶來更高彈性。憑藉董事會豐富的經驗及克服短期挑戰的決心，本集團已準備就緒，繼續全力把握新商機，同時保持審慎及謹慎的態度，以保障股東利益。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及紐西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 30,000 名客戶。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity: The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend: An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management, and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

2025年中期業績表現要點：- 強勁增長：收入總額為港幣20.68億元，較去年同期大幅增長；- 扭虧為盈：報告期內，公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，實現扭虧為盈；- 募資提升：旗下基金資產管理總規模（AUM）約港幣1,194億元，期內新增募資約港幣27.41億元；- 退出良好：基金及自有資金層面合計退出金額港幣20.18億元，退出回報倍數（MOIC）約2.78倍；- 控本增效：強化精益管理，經營成本同比下降10%，財務費用同比下降38%；- 流動性充裕：擁有現金及現金等價物約港幣81億元；- 穩健派息：中期股息為每股港幣0.05元。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) - 中國光大控股有限公司（「光大控股」，股份代號：165.HK）公佈截至2025年6月30日止6個月（「報告期」）之中期業績。2025年上半年，中國私募股權行業逐步邁入更加穩健的發展階段。光大控股充分發揮耐心資本優勢，保持戰略定力，準確把握市場機遇，及時調整募投管退策略，夯實核心主業，價值潛能逐步釋放，公司整體經營質效大幅改善，業績強勁復蘇。報告期內，光大控股實現收入總額為港幣20.68億元，較去年同期大幅增長港幣21.82億元，主要得益於投資收入的大幅增加，充分展現了公司良好的投資眼光和長期投資底蘊。公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，較去年同期淨虧損港幣12.82億元成功實現扭虧為盈，業績顯著改善。與此同時，公司繼續強化精細管理，保持健康穩健的經營發展。期內，經營成本同比下降10%，主動壓減槓桿，計息負債比率對比2024年末減少2%，控本增效成果顯著，財務費用同比下降38%。公司流動性保持充裕，截至2025年6月底，擁有現金及現金等價物約港幣81億元。公司資源和業務重心繼續向優勢產品聚焦，進一步穩固核心主業。報告期內，新增募資約港幣27.41億元，旗下基金資產管理總規模（AUM）約港幣1,194億元，在管基金產品72只，涵蓋一級市場基金、二級市場基金和母基金。期內，共計對9個項目進行投資，完全/部分退出項目46個。秉承與股東分享經營成果的發展理念，董事會宣派2025年中期股息為每股港幣0.05元（2024年中期股息：每股港幣0.05元）。2025年上半年經營要點一、發揮集團化運營優勢，加強募資協同體系2025年上半年，公司新完成設立淮安洪澤光啟基金和廈門海洋高新產業發展基金，總規模為人民幣25億元。淮安基金關注成長階段的新能源、新材料和智能製造等項目，上半年已完成首期實繳到位；廈門海洋基金關注海洋科技成果孵化轉化，助力海洋經濟高質量發展。同時，多只基金已完成立項，目前正按照既定規劃有序推進中。二、穩固核心主營業務，驅動業績強勁復甦報告期內，公司基金及自有資金層面合計退出金額港幣20.18億元，完成小鵬汽車、大普通信、Taboola三筆完全退出，部分退出了軟通動力、德康農牧、第四範式等多個項目，退出回報倍數（MOIC）約2.78倍，全面帶動多只基金DPI提升，為基金LP帶來了可觀收益。Circle、德康農牧、網易雲音樂等已上市項目在上半年均有良好的市場表現，為公司貢獻較好的投資收益。二級市場基金上半年精准把握結構性機會，投資業績表現較好，其中光大可轉債機會基金榮獲巴克萊評選的同類基金業績排名的第二名。三、錨定科技創新戰略，佈局重點行業領域公司基於深刻的產業洞察和前瞻性的戰略視野，在上半年加快投資節奏，重點聚焦人工智慧、芯片半導體、生物醫藥等戰略性新興產業，基金層面合計投資約港幣2.64億元。培育並支持多家科技領軍企業，包括長江存儲和武漢新芯（國產存儲芯片巨頭）、恒翼生物（腫瘤及自免創新藥研發企業）、鈞嵌傳感（國產工業自動化模組及新能源車核心感測器戰略供應商）、鈦動科技（大數據與BI領域服務商）等，支援中國科創企業做優做強。同時通過母基金支持金鎰資本、鐘鼎資本等優秀的子基金，發揮母基金資源放大、風險分散、收益多元的優勢。四、優化經營管理，釋放發展新動能公司持續優化融資結構，上半年把握國內降息週期，發行人民幣30億元的2025年第一期中期票據，年利率2.09%，創公司歷史債券發行票面利率新低。報告期內，公司整體融資成本同比下降 133個基點至 3.14%，財務費用同比下降 38%，經營成本同比下降10%，降本增效成果顯著。公司持續優化風險管理體系，通過推進風險資產分級分類、強化動態估值管理及構建風險監測預警機制，實現全流程風險防控效能提升。五、強化民生服務，商業消費更新升級光大控股發揮旗下產業優勢，提升產品服務品質，以滿足居民日益增長的消費服務需求。商業消費方面，旗下光大安石已在全國9個城市成功打造18座"大融城"購物中心，管理規模約260萬平方米，創造了約3.77萬個工作崗位，2025年上半年累計服務消費者約1.21億人次，服務商戶超過4500個。報告期內，北京重點消費類基礎設施及城市更新項目「中關村ART PARK大融城」一期順利開業，有效帶動消費體驗升級，擴大內需。六、重要投資企業穩中向好，韌性強勁中飛租賃主業發展穩健，經營質量和運營效率持續提升，股東應占淨利潤同比增長。截至2025年6月30日，中飛租賃機隊規模達181架，租賃予22個國家及地區的41家航空公司。光大養老緊抓國內康養產業發展機遇，在全國49個城市擁有各類養老機構數量237個，提供養老床位3萬余張，入住率提高1.77%。特斯聯持續深化AI技術與多產業融合，驅動多行業智慧化升級，落地國產化AI應用與數智方案，並榮獲多項權威認證。七、強化構建ESG體系，推動可持續發展報告期內，公司持續推動ESG體系建設，公司MSCI（明晟）ESG評級維持為A級，並獲得香港投資者關係協會（HKIRA）頒發的「BEST ESG（S）」獎項。公司切實發揮自身所能，履行企業公民責任擔當，上半年共組織及參與各類文化和社會公益活動46次，服務人群超過萬人，高標準履行社會責任。 2025年上半年，在光大集團的堅強領導、董事會的帶領和全體員工的共同努力下，公司經營質效全面改善，發展新動能持續增強，取得來之不易的成績。隨著中國經濟的持續向好，政策支持力度的不斷加強，中國私募股權行業將邁入高質量發展的新征程。光大控股將緊抓市場機遇，乘勢而上，為實現"十五五"良好開局夯基固本。下半年，光大控股將繼續堅持穩中求進的工作總基調，持續做好增收控本，優化經營管理，搶抓"募投管退"等關鍵業務環節的機遇，借助跨境平台和集團綜合協同的勢能，培育長期耐心資本，做好金融「五篇大文章」，通過科學的戰略規劃、專業的投資團隊和嚴格的風險管理，持續為股東創造價值。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天公布截至2025年6月30日止六個月的中期業績。- 新增業務銷售額以按年化新保費計算較2024年同期上升38% 至1,246百萬美元。新業務合約服務邊際為794百萬美元，按年增幅達34%。- 稅後營運利潤增長9%，達251百萬美元。香港特別行政區和澳門特別行政區、泰國和柬埔寨、日本以及新興市場四個地區業務分部持續為集團帶來正面貢獻。- 淨利潤達47百萬美元，錄得採用國際財務報告準則第17號以來中期業績新高。- 富衛集團進一步提升財務靈活性，於2025年7月獲國際信貸評級機構穆迪上調評級，名義保險公司財務實力評級升至A2。償付能力充足率*維持在283%，產生的基本自由盈餘淨額增至417百萬美元，增幅超過一倍，展現穩健的資本狀況。來自各地區業務分部的股息收入超過500百萬美元。- 綜合有形權益上升8% 至8,150百萬美元，集團內涵價值上升8% 至6,380百萬美元，反映富衛集團於2025年上半年為股東創造的價值。富衛其後完成首次公開招股，集資總額達3,611百萬港元（約466百萬美元），並於2025年7月7日正式在香港聯合交易所有限公司主板以股份代號1828掛牌交易。- 完成構建亞洲高資產淨值客戶服務網絡，覆蓋香港特別行政區、新加坡及百慕達三地，為全球高端保險市場客戶提供多元化資產配置、財富管理及傳承規劃。全新的FWD Private 貴賓室坐落於香港黃金商業地段，現已全面投入運作。富衛集團行政總裁兼執行董事黃清風表示：「我們非常高興首次以上市公司身份公布業績，就創出採用國際財務報告準則第17號以來的中期業績新高。新業務合約服務邊際的強勁增長，展現了我們成功在亞洲貫徹以客為先策略實現可持續盈利的能力。」黃清風補充：「我們計劃將近期首次公開招股所得款項淨額用於進一步提升資本實力及財務靈活性，包括減少整體債務，以支持業務增長及拓展客戶及渠道覆蓋滲透的機會，如深化數碼能力及策略。」在香港特別行政區及澳門特別行政區，新增業務銷售額及新業務合約服務邊際均錄得顯著增長，反映本地及中國內地訪客客群持續多元的需求，以及富衛高資產淨值客戶服務全面啟動帶來的正面影響。富衛集團持續專注於多渠道分銷模式策略，並積極推動產品創新，包括根據最新監管指引所開發的指數型萬用壽險產品，以及為合資格客戶推出的大灣區跨境醫療服務。泰國與柬埔寨的業務分部新業務指標部分受到2024 年退出泰國團體醫療保險業務新單承保的影響。泰國業務具備優越條件，能夠滿足人口老化所帶來的保障、醫療及退休產品需求。其與泰國匯商銀行之獨家銀行保險合作關係保持市場第一的地位。此外，富衛泰國的代理人與顧問在 2025 年 7 月公布的百萬圓桌排名中繼續名列第二。百萬圓桌會是一個獨立國際組織，獲公認為人壽保險及金融服務業的卓越標準。日本憑藉以個人保障為核心的產品組合錄得穩健的新業務成果。公司於7月推出日圓整付保費年金產品，是公司在日本的首個儲蓄產品，標誌著富衛進軍儲蓄與退休需求市場。新興市場分部旗下數個市場在面臨行業不利因素與經濟不確定性的情況下，仍錄得強勁的新業務銷售成長。在印尼，富衛集團持有 44% 策略性投資並與印尼人民銀行的合資企業印尼人民銀行人壽保險（ BRI Life），在銀行保險新業務銷售方面位居第一。在菲律賓與越南，公司的代理人與顧問在最新公布的百萬圓桌排名中名列第二。 截至六個月止／於12月31日或6月30日^ 百萬美元，百分比除外2025 2024增長(以固定匯率按年計算) 盈利 稅後營運利潤2512239% 淨利潤/(虧損)473無意義 合約服務邊際5,9965,17411% 增長 新增業務銷售額1,24687638% 新業務合約服務邊際79457334% 新業務價值50640421% 客戶指標 客戶投保評價 –「好」或「非常好」92%92%不適用 客戶索償權益-索償的淨推薦值6364不適用 風險與資本 產生的基本自由盈餘淨額417193115% 集團當地資本總和法覆蓋率*283% 260%不適用 價值 集團內涵價值6,3805,5698% 綜合有形權益8,1507,1628% 有形權益回報率17%15%不適用 關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務約3,400萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.com^ 所有業績數據均截至 2025年6月30日並與2024年同期比較。合約服務邊際結餘、集團當地資本總和法覆蓋率、集團內涵價值、綜合有形權益及2024年權益回報則為2024年12月之結餘／比率和增長率。增長率按固定匯率計算。除稅後營運利潤/（虧損）（非國際財務報告準則計量指標）、淨利潤/（虧損）、合約服務邊際及綜合有形權益外，其他數據均未經審計師審核。稅後營運利潤及稅後淨利潤為公司股東應佔部分，並已扣除非控股權益。新業務銷售以年化新保費100%及整付保費10%組合計算。有形權益回報的計算方式為稅後營運利潤除以期初及期末的有形權益平均值。有形權益的計算方式為經調整後公司股東應佔權益總額，減去扣除非控股權益後的無形資產。* 根據訂明資本要求基準 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 天能動力國際有限公司(「公司」，連同其附屬公司，統稱「集團或天能」）（股份代號：00819.HK)公布截至2025年6月30日止六個月（「報告期內」）之中期業績。2025年上半年，天能堅持戰略引領、改革破局的總體思路，統籌推進實業、科技、資本三輪驅動戰略。在鞏固鉛蓄電池業務核心競爭力的同時，加速海外市場開拓，推動新能源電池業務從積累轉向釋放，深化電池循環體系的縱深建設，驅動業務全景化、可持續發展。報告期內，集團實施聚焦主業、主動收縮貿易業務戰略，實現制造業營業收入約人民幣211.68億元，較去年同期基本持平，占整體營業收入比例提升至約87.5%；實現貿易業務營業收入約人民幣30.24億元，較去年同期下降約89.47%，占整體營業收入比例下降至約12.50%。製造業中，高端環保電池業務穩築基本盤，為戰略轉型提供堅實的財務後盾。新興業務高速增長，其中，鋰離子電池業務取得營業收入約5.01億元，較去年同期躍升174.58%。報告期內，集團實現毛利額約人民幣25.37億元，較去年同期基本持平；經營現金流釋放躍升，由去年同期約人民幣1.62億元淨現金流出轉變至約人民幣8.91億元淨現金流入。綜上，2025年上半年，在複雜外部環境下，天能展現出強大經營韌性、發展動能和戰略執行力。國際化進程加速 海外市場拓展成果顯著國際化布局是集團提升全球競爭力、實現增量跨越的重要戰略支點。2025年上半年，海外業務呈現突破性增長，市場反饋持續向好，實現營業收入約人民幣2.26億元，較去年同期增長約75.39%。報告期內，集團以當地需求為導向，結合海內外產業資源加速國際市場開拓，於泰國、越南、土耳其等地配置本地運營團隊，發展數十家授權經銷商，銷售網絡覆蓋亞太、歐美、中東非各地區主要國家。越南生產基地建設有序推進，組裝基地產能全面釋放，為區域深耕奠定基礎。針對性開發本地化產品，滿足差異化需求；重點建設本地化渠道與運營團隊；同步推進“服務出海”戰略，系統性構建本地化服務標準體系。優化全球供應鏈，釋放增長動能。主業穩中見韌 蓄勢動能長青 報告期內，集團在複雜外部環境與產業結構再平衡的背景下，堅持「穩中求進，以進促穩」的經營節奏。高端環保電池業務表現堅實，上半年取得營業收入約人民幣182.92億元，為集團穩健續航持續注入動力。高端環保電池是集團基於研發與工藝創新打造的密封型免維護鉛蓄電池，深度適配電動輕型車市場需求，憑借其綜合成本及性能優勢，亦廣泛應用於備用電源、汽車電池與電動特種工業動力電池等領域。集團秉持核心業務優勢，深化智能制造升級、精進運營管理體系、鞏固銷售渠道網絡，驅動產品質量持續提高與綜合市場競爭力不斷增強，強化鉛蓄電池業務在複雜市場環境下的發展韌性。報告期內，集團通過智能制造體系應用與設備技術改造升級，有效提升制造效能與供應鏈保障能力，成本管控成效逐步顯現；依托電池技術迭代驅動產品性能升級，圍繞電動輕型車、數據中心、汽車起動啟停與工業動力等重點場景，形成差異化產品矩陣；驅動以用戶價值為核心的服務體系升級，深度整合傳統經銷網絡與創新數字生態。深化多元技術路線 加快業務增長新動能2025年上半年，集團錨定新能源業務發展方向，圍繞鋰離子電池、固態電池、氫燃料電池、鈉離子電池等多技術路徑，系統推進研發攻關、智能制造與場景拓展，加快培育業務增長新動能。集團鋰離子電池主要聚焦儲能與低速動力等領域。報告期內，集團儲能與低速動力業務實現量的躍升與質的改善，工業電池及駐車空調電池等細分市場增量空間得以拓展，產能利用率明顯提升，整體營收顯著增長，經營質效明顯改善，取得營業收入約5.01億元，較去年同期增長約174.58%。集團固態電池研發取得階段性進展，重點突破高比能、長循環及高倍率三大方向，與頭部兩輪車企業建立戰略合作關系，並在低空飛行器領域與相關企業推進解決方案驗證。集團在氫燃料電池持續投入，擁有全鏈條研發體系和專家團隊，產品性能先進，在兩輪車、公交、重卡及特種機械等場景推進示範驗證，並與上下遊合作夥伴共同構建應用生態。集團同步推進鈉離子電池技術與應用布局，報告期內圍繞汽車起動啟停與儲能等應用場景開展低溫與循環壽命等關鍵指標驗證，保持穩健的產業化節奏。通過多技術路徑的協同，遵循「技術攻堅—場景驗證—方案化交付」的推進節奏，集團新能源電池業務增長動因正由點式驗證向鏈條釋放有序過渡，業務動能得到紮實支撐。夯實循環體系 強化產業協同新動能集團專注於電池產業，系統構建覆蓋生產、回收、再利用的全生命周期產業鏈，形成鉛蓄電池和鋰離子電池雙軌循環產業體系，實現資源高效再生利用。報告期內，集團可循環產業實現對外營業收入約人民幣18.00億元，較去年同期增長約15.82%。作為國內循環產業的領先企業，集團著眼於構建兼具前端觸達能力與後端處理效率的高效回收網絡，以規模化的處置能力和業務協同優勢推動廢舊電池資源有效利用，關鍵材料回收率居於行業前列。報告期內，集團持續貫通回收、處置與再利用全流程，提升鉛蓄電池回收渠道整合力與運營精度；強化鋰離子電池回收差異化路徑布局，深化核心區域與重點場景資源聯動。集團通過深挖技術潛能與優化系統表現，逐步釋放循環體系的規模優勢與經濟價值，為產業注入持久動能。展望未來，天能將以技術革新驅動產業升級，以數智化賦能運營增效，以生態協同重塑價值鏈體系，以全球化布局開拓增量空間，鞏固鉛蓄電池核心主業優勢，加快推進鋰離子電池、固態電池等新能源電池的研發、應用與市場開拓，強化電池回收與資源再生能力，提升產業鏈一體化水平與協同效率。天能將同步加速海外市場布局與本地化經營能力建設，向制造與服務體系延伸，構建發展為具備長期競爭力和全球視野的新能源電池產業格局企業。天能將持續推動企業價值與社會價值深度融合、共同成長，打造可持續、高質量增長的創新範式。關於天能動力國際有限公司天能動力國際有限公司及其附屬公司創立於一九八六年，總部設於中國，憑借完善的制造體系與技術優勢，發展成為新能源電池行業領先企業及輕型電動車電池領域龍頭企業，二零零七年於香港聯合交易所有限公司主板上市（股份代號：00819.HK）。曆經近四十載發展，集團以鉛蓄電池為核心主業，深耕電動輕型車動力電池市場，並拓展至備用電源、汽車電池與工業動力電池等多元領域。集團為全面布局未來新能源生態，在堅守主業優勢的基礎上，積極推進鋰離子電池、固態電池、氫燃料電池及鈉離子電池的研發、生產與銷售，以多技術路線產品矩陣覆蓋多元新能源應用場景，並同步構建循環經濟產業鏈，依托廢舊鉛蓄電池與廢舊鋰離子電池循環利用業務，推動資源高效再生。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Tianneng Power International Limited (the “Company”, together with its subsidiaries, collectively referred to as the “Group” or “Tianneng”), (Stock Code: 00819.HK) releases its interim report for the six-month period ended 30 June 2025.In the first half of 2025, adhering to the Group’s vision of Strategic Guidance and Reformation Breakthrough, Tianneng coordinated the three-wheeled strategy of Industry, Technology, and Capital. While solidifying the core competency of the lead-acid battery business, the Group also accelerated the expansion of overseas markets, released the Group’s built-up potential in new-energy battery, deepened the vertical construction of the battery recycle system, and drove the diversification of products and sustainability.Within the reporting period, the Group made a strategic pivot to reduce the trade business, achieved RMB 21.168 billion in revenue for the manufacturing business, which was stable compared to the same period in 2024, accounting for approximately 87.5% of the total revenue within the sector. In terms of the trade business, the Group realized an overall revenue of RMB 30.24 billion, which represented an 89.47% decrease from the same period of 2024. Within The manufacturing sector, the high-end eco-friendly battery business remained stable, providing a resilient financial support for the Group. The emerging businesses experienced significant growth, among which the Li-ion battery business achieved a revenue of RMB 0.501 billion, representing a 174.58% growth from the same period of 2024. Within the reporting period, the Group achieved a gross profit of RMB 2.537 billion, which is stable compared to the same period of 2024. In terms of operating cash flow, the Group achieved RMB 0.891 billion of net inflow, compared to a net outflow of RMB 0.162 billion in the same period of last year. Overall, in the first half of 2025, Tianneng demonstrated strong resilience, developmental momentum, and strategic commitment in a complex external environment.Internationalisation Accelerated, Overseas Expansion Bore FruitsInternational expansion is a vital fulcrum of the Group in strengthening global competitiveness and achieving incremental leaps. In the first half of 2025, the overseas business experienced remarkable growth with continuous positive feedback, achieving a revenue of RMB 0.226 billion, representing a 75.39% growth from the same period of 2024.Within the reporting period, guided by local demands, the Group accelerated its overseas expansion with global industrial resources, and set up operational teams in countries such as Thailand, Vietnam, and Turkey while developing a sales network in major areas including the Asia-Pacific, Europe, North America, the Middle-East and Africa. In addition, the Group’s production base in Vietnam is being constructed in an orderly manner while the capacity of the assembly base is robustly released, laying the groundwork for future developments in the region. The Group has developed customised products based on specific local demands and emphasised building localised operational teams, while advancing its “Overseas Service” strategy, and systematically constructed localised standards. With these developments, the Group was able to optimise its global supply chain and release future growth potentials.Core Business Stable and Resilient, with Promising Growth MomentumWithin the reporting period, the Group pursued a path of “Stability and Growth Duality” under a complex external environment and industrial structure re-balancing. The high-end eco-friendly battery business demonstrated resilience, achieving a revenue of RMB 18.292 billion, providing the vital financial stability for the Group. The high-end eco-friendly batteries are sealed, maintenance-less lead-acid batteries built with the Group’s innovation in design and manufacturing, highly adapting to the demands of the light electric vehicle market, with their cost and performance superiority, are also widely utilised in various fields, including backup power supplies, automobile batteries, and special-purpose industrial power batteries.The Group solidified its competencies in the core business, upgraded its intelligent manufacturing capabilities, improved the operational management system, consolidated its sales network, drove product quality and comprehensive market competitiveness growth, and fortified the resilience of lead-acid batteries in a complex market environment. Within the reporting period, the Group was able to effectively upgrade its manufacturing efficiency and supply-chain resilience through utilising intelligent manufacturing systems and equipment technology upgrades, while demonstrating effective results in cost management. Through the evolution of battery technologies and product upgrades, the Group constructed a differentiated product matrix targeting major fields of usage such as light electric vehicles, data centres, automobile start-stop batteries, and industrial power batteries,driving a service system upgrade with user value at its core, and organically merged the traditional sales network with an innovative digital ecosystem.Solidifying the Diversity of Technological Road-maps and Accelerating New Business Growth In the first half of 2025, the Group committed to the development of new-energy businesses, including Li-ion batteries, solid-state batteries, hydrogen fuel cells, and sodium-ion batteries, and systematically drove innovative breakthroughs, intelligent manufacturing upgrades, user-scenario extensions, and fostered new business growth. The Group’s Li-ion batteries business mainly targets power storage and low-speed power. Within the reporting period, the Group’s power storage and low-speed power business achieved major improvements both in terms of quality and quantity. Specific markets, such as industrial batteries and automobile A/C batteries, also saw improvements in market volume. Overall, the capacity utilisation of the Group’s new-energy business was significantly enhanced, with remarkable improvements in operational efficiency and revenue, RMB 0.501 billion, a 174.58% increase from the same period of 2024.The Group’s solid-state battery also achieved intermittent success within the three dimensions of high energy density, cycle longevity, and high-rate performance. The Group also formed strategic collaborations with industry leaders in the two-wheeled vehicle market and carried out solution testing with partners targeting the low-altitude flying vehicle market. The Group continued its investment in hydrogen fuel-cells with a full-chain R&D system and an expert team, with advanced products, began testing in user-scenarios such as two-wheeled vehicles, public transportation, heavy trucks, and special-purpose machinery, and collaborated with upstream and downstream partners in constructing an application ecosystem. The Group also spearheaded the development and application of sodium-ion battery technology, and conducted experiments for key metrics such as low-temperature and cycle longevity testing for scenarios such as power storage and automobile start-stop battery in a steady manner. Through the multi-roadmap approach, and the “technology breakthrough - user scenario verification - solution delivery” process, the Group’s new-energy business growth is gradually and steadily shifting from individual verification to chain-release, firmly supporting the business momentum.Strengthening the Recycling System and Fortifying Industrial CollaborationThe battery industry is at the core of the Group’s business, which systematically constructed a full-life industry chain of manufacturing, recycling, and reusing, forming a two-railed industry system of lead-acid battery and Li-ion battery, achieving efficient recycling. Within the reporting period, the recycling business of the Group achieved a revenue of RMB 1.8 billion, a 15.82% increase compared to the same period of 2024.As a leader in the recycling industry in China, the Group is continuously building an effective recycling network with front-end reach and back-end efficiency, promoting the efficiency of waste battery recycling empowered by the collaborative effort of businesses at scale, and achieving a top-of-industry recycling ratio of crucial materials. Within the reporting period, the Group continued to enhance the granularity and precision of the recycling process from recycling, processing, and reusing, improve the differentiating system for Li-ion battery recycling, and improve the resource synergies at core regions and user scenarios. Through uninterrupted exploration of technological potential and system performance optimisation, the Group was able to gradually achieve scale advantage and economic value of the recycling system, injecting continuous momentum for the industry.Looking forward, Tianneng will drive industrial upgrades through technological innovation, empower efficient operation through digitisation, rebuild the value-chain system through ecological collaboration, and seek growth through internationalisation. The Group will solidify its competencies in the lead-acid market, accelerate the research, application, and market expansion process of new energy batteries such as Li-ion battery and solid-state battery. The Group will strengthen its capabilities in battery recycling, enhance the collaborative efficiency of industry-chain integration while expediting its expansion into overseas markets and optimising localised operation, from product to service, and develop into a new-energy battery company that is competitive with a global vision. Finally, the Group will promote the convergence between its company values and social values with a growth mindset and build a new paradigm of sustainable and high-quality growth.About Tianneng Power International LimitedTianneng Power International Limited and its subsidiaries (collectively referred to as “Tianneng” or the “Company”), founded in 1986 and headquartered in China, has developed into a leading enterprise in the new energy battery and the light electric vehicle battery industry with a comprehensive manufacturing system and technological advantage. Tianneng was listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 00819. HK) in 2007. After nearly four decades of development, Tianneng has established lead-acid batteries as its core business, focusing on the market of motive batteries for light electric vehicles, while expanding its product in automotive start-stop systems, backup power for communication base stations and other diversified scenarios. The Company is also advancing the R&D, production and sales of lithium-ion batteries, hydrogen fuel cells, sodium-ion batteries and solid-state batteries, offering multi-technology battery solutions for special industrial vehicles, energy storage systems and other applications. Additionally, Tianneng strengthens its recycling economy initiatives around its core operations. Through a dual-track system for lead and lithium recycling, the Company achieves efficient resource regeneration and reuse, building a comprehensive ecosystem for the new energy industry. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2025年6月30日止（「報告期」）之中期業績。集團以「一橫一縱」為主要經營策略，橫向輸出精益運營體系，推進醫聯體多模式合作，縱向聚焦專科方向上的醫檢聯合創新，加速新技術新產品轉化及應用推廣，同時以AI賦能醫聯體整體解決方案，推動AI在醫療場景的實際應用，持續強化臨床賦能價值，呈現強大的經營韌性。2025年上半年，受集採、醫保控費及行業競爭加劇等多方面因素影響，導致集團短期業績未達預期，然而集團始終堅持產品創新和模式創新，並進一步完善企業經營管理的機制和流程，堅持精益運營，整體經營取得明顯成效。報告期內，集團毛利率約為34.0%，較2024年度整體毛利率提升約4.4%；虧損淨額人民幣55.4百萬元，較上年同期減少56.1%，明顯收窄。此外，醫聯體共建業務板塊持續為集團第一大業務板塊，錄得收益人民幣180.3百萬元，佔總收益的57.6%，較上年同期提升約9.6%，在深度服務賦能醫聯體客戶方面成效顯著，為集團長期高質量發展奠定基礎。報告期內，集團診斷檢測服務錄得收益人民幣313.2百萬元。一橫一縱策略穩步實施，院企合作成效明顯「一橫」——輸出精益運營體系，深化醫聯體多模式合作雲康一直致力於發展「以專業化為基礎、標準化為核心、數智化為手段、協同化為目標」的醫聯體共建創新服務模式。報告期內，集團已為近450家醫聯體客戶提供不同臨床需求的多場景解決方案，包括AI+醫聯體數智化解決方案、醫學實驗室整體合作、區域╱病理中心解決方案、精準醫學中心解決方案、專科聯盟建設解決方案等多模式合作。透過發揮雲康優勢，協助各級醫療機構提升服務能力、外拓服務範圍，構建分級協同的醫療服務體系，促進區域分級診療發展。報告期內，雲康持續與頭部引領型醫院、各地區市縣級醫院展開深度合作，在市場競爭形勢日趨嚴峻的情況下，醫聯體共建業務板塊仍保持穩健發展，競爭優勢進一步鞏固。「一纵」——醫檢聯合創新平台打造科研創新強引擎集團始終聚焦「臨床需求」，不斷加強院企合作，首創性打造「醫檢聯合創新平台」，助力集團業務開拓及提升產品競爭力。報告期內，集團已與全國數十家頂級醫療機構開展醫檢聯合創新合作，累計成功開發出數十項針對呼吸道感染、中樞神經系統感染、泌尿系統感染、婦科感染、結核感染等多領域的不同感染症候群檢測產品，以及個性化用藥基因檢測產品，創新產品累計服務客戶近300家，檢測收益持續增長。報告期內，雲康與廣東省人民醫院先後上市呼吸道感染、中樞神經感染、侵襲性真菌感染等系列新panel產品，成功構建國內院企科研創新轉化標準化孵育模式和「1+N」醫檢協同網絡，此外，雙方在科研創新過程中，積累了豐富的臨床經驗，在數十位國內臨床、檢驗等多領域專家學者的積極參與和持續推動下，形成了《tNGS臨床規範化應用專家共識》，並於報告期內在國內檢驗頂級期刊《中華檢驗醫學雜誌》發佈。報告期內，雲康亦與國內頂尖醫院廣州醫科大學附屬第一醫院緊密合作，成功開發泌尿tNGS產品，推動尿路感染精準診療的臨床實踐。同時，雲康與暨南大學附屬第一醫院聯合打造「校院企聯合創新平台」，孵化和運營「精神疾病藥物基因檢測創新項目」，並成功開發出抗抑鬱藥物基因檢測、抗焦慮及鎮靜安眠藥物基因檢測產品。AI賦能醫聯體多模式解決方案，提質增效深化客戶服務報告期內，雲康全面接入DeepSeek，實現集團數字化平台部署。雲康以「AI+」與「精準診斷」為核心理念，將人工智能技術廣泛應用於旗下醫學實驗室的多技術平台。以AI技術與雲康病理診斷平台的深度融合為例，雲康病理檢測流程被極大壓縮，單切片AI診斷效率持續優化，實現智能、效率、質量三重提升。此外，透過部署智能化功能應用，雲康已實現智能在線客服、結果與報告高效審核等功能，全面優化醫檢服務的流程，提升客戶服務體驗和滿意度。在院企聯合研發新技術新產品過程中，借助AI大模型強大的數據分析、模型構建和智能預測能力，雲康AI技術從生信分析、報告解讀、疾病風險評估、創新產品研發轉化等多方面賦能產品創新研發，加速產品落地臨床。值得一提的是，雲康攜手潤達醫療、華為共同開發的醫療大模型「智雲」已重磅發佈，覆蓋了診前、診中、診後的全流程場景，將為臨床醫療服務全流程提供更加高效、便捷的支持和體驗。同時，雲康與潤達醫療簽署戰略合作協議，以強化「AI+IVD+醫療服務」在產業生態鏈之間的深度合作，並共同推動人工智能大模型在醫療端的發展與應用，為客戶提供數智化的醫療解決方案。未來，「智雲」醫療大模型將在雲康合作醫療機構中試點應用，並逐步推廣至全國，為醫聯體建設運營提質增效。未來展望2025年是「十四五」規劃的收官之年，國家推動優質醫療資源加快擴容下沉，促進區域佈局更加均衡，同時不斷加快醫聯體建設，推動其由「搭框架」向「高質量運營」升級。臨床治療亦正從「廣譜治療」邁向「精準化治療」新階段，行業增長潛力持續釋放。同時，AI技術持續賦能分級診療，行業將迎來發展新機遇。展望未來，雲康將繼續緊跟行業發展脈搏，以國家政策為導向，不斷強化臨床賦能價值，持續探索「產品創新+模式創新」雙輪模式，加速業務開拓，深度賦能醫學檢測服務，惠及更多居民。雲康集團有限公司（股份代號：2325）雲康集團是中國領先的醫學運營服務提供商，早於2008年雲康便開始面向各級醫療機構提供標準化的醫療診斷服務，透過利用自身專業的診斷能力以及覆蓋全國的醫聯體服務網絡，逐漸發展成為醫學運營服務的領先平台。雲康也是中國領先的醫聯體診斷服務供應商，提供涵蓋醫聯體診斷及診斷外包的全方位醫療健康服務。雲康向中國醫聯體內的合作醫院提供診斷檢測服務，透過現場診斷中心協助其提升臨床診斷能力。迄今為止，雲康已成功為來自全國近450家現場診斷中心提供專業服務，截至2025年6月30日，雲康合作的醫院分佈於中國31個省市。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its interim results for the six months ended 30 June 2025 (the "Reporting Period"). The Group adopted “one horizontal, one vertical” as its core business strategy: horizontally, it extended a lean management system to advance multi-mode collaboration among medical institution alliances; vertically, it focused on specialty-specific innovation in medical diagnostics to fast-track the translation and implementation of new technologies and products. Meanwhile, the Group leveraged AI to enhance the comprehensive solutions for medical institution alliances, promoted the practical application of AI in healthcare scenarios, and continuously strengthened the value of empowering clinical practices, demonstrating strong operational resilience.In the first half of 2025, due to multiple factors, including the centralized drug-procurement program, cost controls of medical insurance, and fierce market competition, the Group’s short-term results did not meet expectations. However, the Group remained committed to product and business model innovation, and further refined the mechanisms and processes of its operational management. By adhering to lean operations, the overall performance has achieved significant improvements. During the Reporting Period, the Group’s gross profit margin reached approximately 34.0%, representing an improvement of approximately 4.4% over the overall gross profit margin for 2024. The net loss amounted to RMB55.4 million, a significant decrease of 56.1% compared to the same period last year. The joint construction business remained the Group’s largest business segment, which recorded the revenue of RMB180.3 million, accounting for 57.6% of the total revenue, increased by approximately 9.6% as compared with the same period last year, achieving significant outcomes in empowering medical alliance clients through in-depth services, paving the way for the Group’s long-term high-quality growth. During the Reporting Period, the Group’s diagnostic testing services recorded revenue of RMB313.2 millionSteadily implementing “one horizontal, one vertical” strategy, with notable achievements in hospital-enterprise partnerships“One horizontal” ——Extending lean management system to deepen diverse forms of collaboration within medical institution alliancesYunkang has been committed to developing an innovative service mode for the joint construction of medical institution alliances featuring “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. During the Reporting Period, the Group provided nearly 450 alliance clients with multi-scenario solutions tailored to different clinical needs, including AI+ digital intelligence solutions for medical institution alliances, comprehensive collaborations with medical laboratories, solutions for regional/pathology centers and precision medicine center, and specialty-based solutions for alliance development, among other multi-model collaboration services. By leveraging Yunkang’s strengths, the Group assisted healthcare institutions at all levels in enhancing service capabilities and expanding service coverage, established a hierarchical and coordinated healthcare service system, and promoted the development of regional hierarchical diagnosis and treatment services.During the Reporting Period, despite increasingly fierce market competition, the Group maintained solid growth in the joint construction business through continuous deep collaboration with leading hospitals and municipal and county-level hospitals, further consolidating its competitive advantage.“One vertical” ——Joint innovation platform for diagnostic testing serves as strong driver for R&DThe Group has always focused on “clinical needs”, continuously strengthening hospital-enterprise collaboration and pioneering the establishment of a joint innovation platform for diagnostic testing, driving business expansion and product competitiveness. During the Reporting Period, the Group forged joint diagnostic innovation partnerships with dozens of top-tier medical institutions nationwide, delivering a portfolio of testing products addressing multiple infectious syndromes, including respiratory tract infections, central nervous system infections, urinary tract infections, gynecological infections, and tuberculosis, as well as genetic testing products for personalized medication. Collectively, these innovative products have served nearly 300 clients across the country, and achieved sustained growth in testing revenue.During the Reporting Period, Yunkang and Guangdong Provincial People’s Hospital successively launched a series of new panel products covering respiratory tract infections, central nervous system infections, and invasive fungal infections, successfully creating a standardized incubation model for domestic hospital-enterprise research innovation and translation, as well as a “1+N” medical inspection collaboration network. Moreover, throughout the process of scientific and technological innovation, both parties have gained rich clinical experience. With the active involvement and sustained efforts of dozens of domestic diagnostic experts and scholars, they formulated the Expert Consensus on the Application of tNGS for Clinical Standardization, which was published during the Reporting Period in Chinese Journal of Laboratory Medicine, a leading journal in China’s diagnostic field. During the Reporting Period, Yunkang also maintained close collaboration with the First Affiliated Hospital of Guangzhou Medical University, one of China’s top-tier hospitals, and successfully developed a urinary tNGS product, advancing the clinical practice of precision diagnosis and treatment for urinary tract infections. Simultaneously, Yunkang partnered with the First Affiliated Hospital of Jinan University to establish a “university-hospital-enterprise joint innovation platform” and incubated and operated the “innovation project of psychiatric drug genetic testing”, which has successfully yielded genetic testing products for antidepressants, anti-anxiety drugs, and sedative-hypnotics.AI empowers multi-modal solutions for medical institution alliances, improving quality and efficiency to deepen client services During the Reporting Period, Yunkang fully employed DeepSeek and achieved digital deployment across its platforms. Centered on the core concepts of “AI+” and “precision diagnostics”, Yunkang extensively applied artificial intelligence technology across the multi-technology platforms of its medical laboratories. Taking the in-depth integration of AI technology with Yunkang pathology diagnosis platform as an example, the per-slide efficiency of AI-empowered diagnostic was continuously optimized, achieving simultaneous improvements in intelligence, efficiency, and quality. Moreover, through the deployment of intelligent applications, Yunkang realized smart online customer services and the efficient review of results and reports, which fully streamlined diagnostic service processes and improved experience and satisfaction of its client services. In the process of jointly developing new technologies and products through hospital-enterprise R&D, Yunkang’s AI technology empowered product innovation and R&D across multiple aspects, including bioinformatics analysis, report interpretation, disease risk assessment, and development and translation of novel products, by leveraging the powerful data analysis, modeling, and predictive capabilities of large-scale AI models. This has accelerated the clinical implementation.Notably, Yunkang unveiled its medical AI model “ZhiYun” developed in collaboration with Runda Medical and Huawei, spanning the entire clinical workflow from pre-diagnosis to diagnosis and post-diagnosis. It will provide more efficient and convenient support and experience across all stages of clinical medical services. Meanwhile, Yunkang signed a strategic cooperation agreement with Runda Medical to strengthen in-depth collaboration across the industrial ecosystems in “AI + IVD + healthcare services”, jointly promoting the development and application of large-scale AI models in the medical field, and providing clients with digital-intelligence healthcare solutions. In the future, “ZhiYun”, the medical AI model, will be piloted in Yunkang’s healthcare partners and gradually rolled out nationwide, to improve quality and efficiency of medical institution alliance operations.Future prospects2025 marks the final lap for implementing the 14th Five-Year Plan. China has accelerated the capacity expansion of premium healthcare resources and their extension to lower-tier markets, resulting in a more balanced regional distribution. The country has also expedited the development of medical institution alliances and driven their upgrade from “framework building” to “high-quality operation”. Clinical treatment is also shifting from “broad-spectrum therapies” to “precision medicine”, with the growth potential of the industry continuing to be realized. At the same time, AI technology has continued to empower hierarchical diagnosis and treatment services, and the industry is embracing new growth opportunities. Looking ahead, Yunkang will continue to keep pace with industry development trends and align with national policies, further strengthening the value of empowering clinical practices, and persistently exploring the “product innovation + business innovation” dual-pronged model to accelerate business development, deeply empower medical testing services, and benefit more residents.Yunkang Group Limited (Stock Code: 2325)Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to nearly 450 on-site diagnostic centers. As of June 30, 2025, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Toronto, ON, August 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digital Shovel, a leading innovator in crypto mining infrastructure solutions, is thrilled to announce the successful completion of its partnership with IREN (formerly Iris Energy Limited), marked by the delivery of the final batch totaling 493 MW of busway sets, including active units and spares. This milestone, achieved well ahead of schedule, underscores Digital Shovel’s commitment to excellence and reliability in supporting next-generation data center operations.The partnership, formalized in February 2024, saw Digital Shovel supply IREN with almost 500 MW of busways, critical to powering IREN’s expanding data centers, which are optimized for Bitcoin mining and AI cloud services using 100% renewable energy. The project was completed without delays, with deliveries consistently surpassing expectations, enabling IREN to advance its operational timeline.“We are incredibly proud of the seamless execution of this partnership with IREN,” said Scot Johnson, CEO of Digital Shovel. “Delivering all 493 MW of busway sets ahead of schedule is a testament to our team’s dedication and the strength of our innovative solutions. IREN’s vision for sustainable, high-performance data centers aligns perfectly with our mission, and we’re excited about the impact this project will have on their growth.”The early completion of this contract also positions both companies for future collaboration. “This project has been a fantastic opportunity to showcase what we can achieve together,” Johnson added. “We’re eager to explore new ventures with IREN as they continue to lead in renewable energy-powered data centers for Bitcoin mining and AI applications.”The success of this deployment lays the foundation for expanded collaboration as demand for infrastructure solutions continues to surge. With proven capacity to deliver at scale and speed, Digital Shovel is positioned to help power the next generation of energy-efficient data centers across North America.For more information about Digital Shovel and its solutions, please visit www.digitalshovel.com.About Digital ShovelDigital Shovel is a leading vertically integrated HPC, AI and Bitcoin Mining systems manufacturer, building critical elements for datacenter construction. This includes turnkey modular datacenters, as well as infrastructure including switchgear, Smart PDUs, busway systems and more. For more info, visit www.DigitalShovel.com About IRENIREN (NASDAQ: IREN), formerly Iris Energy Limited, is an Australia-based company operating next-generation data centers powered by 100% renewable energy. With facilities optimized for Bitcoin mining, AI cloud services, and other power-dense computing applications, IREN is a global leader in sustainable, high-performance data center solutions. For more information, visit www.iren.com.Media Contact:Press@DigitalShovel.comhttps://www.digitalshovel.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has agreed to a multi-year partnership as the new title sponsor of The Palm Beaches Marathon. The U.S. Polo Assn. Palm Beaches Marathon, a race owned and managed by Ken Kennerly's K2 Sports Ventures, will be held in Downtown West Palm Beach, Florida, on December 13-14, 2025.USPA MarathonThis renowned marathon event is recognized for its beautiful views of the waterfront and palm-tree-lined streets and welcomes runners from across the country and around the world to the warmth of Florida during the cold winter months. It is also a qualifier for the legendary Boston Marathon."U.S. Polo Assn. is honored to be the Title Sponsor of The Palm Beaches Marathon, an iconic event that, like our brand, is deeply rooted in this vibrant community of Palm Beach County," said J. Michael Prince, President and CEO of USPA Global, the company that oversees the global, multi-billion-dollar U.S. Polo Assn. brand. "While our sport-inspired brand has a worldwide footprint in more than 190 countries, our heart and heritage are right here in The Palm Beaches, home to USPA Global, the United States Polo Association, and the USPA National Polo Center, the most prestigious polo destination in the world."The race weekend will include the 5K and 10K at 7:30 a.m. Saturday, December 13, followed by the featured Marathon, Half Marathon, and Marathon Relay on Sunday, December 14 at 6 a.m. Early registration is now open. Cost is $130 for the Marathon and $100 for the Half Marathon. The early registration fee for the 10K is $60, and $45 for the 5K. To register for The U.S. Polo Assn. Palm Beaches Marathon, visit palmbeachmarathon.com.A Health and Fitness Expo will coincide with race packet pickup on Friday, December 12, from 12 p.m. to 6 p.m. and Saturday, December 13, from 10 a.m. to 6 p.m. at the Meyer Amphitheatre, 104 Datura St., West Palm Beach. The Expo will feature the latest in health and fitness products and services, running apparel, and upcoming race information."We are excited to add a renowned global brand like U.S. Polo Assn. as the Title Sponsor of The Palm Beaches Marathon," Kennerly said. "This is a massive deal for the future of our race and its appeal to runners throughout the world. The Palm Beaches are a globally recognized blue-chip destination, and we are looking forward to continuing to grow the race not only in our community, but also on an international level."U.S. Polo Assn. brand products include apparel for men, women, and children, as well as accessories, luggage, watches, shoes, home furnishings, and more, with distribution across 190 countries through independent retail stores, department stores, U.S. Polo Assn. brand stores and e-commerce."Partnering with The Palm Beaches Marathon allows us to celebrate athletic excellence, community spirit, health and wellness, as well as the shared passion for sport that connects us locally and around the world. From the polo fields to the streets of Palm Beach, we are inspired by the athletes who give their all, and we look forward to sharing in the energy, camaraderie, and world-class competition that make The Palm Beaches Marathon truly special," Prince added.The race will support local charities, soon to be announced.WPBF 25, the Hearst-owned ABC Affiliate, will return as the Official Broadcast Station of the race and will provide extensive pre- and post-race coverage on all on-air and digital channels, as well as produce a live broadcast on Marathon race morning."WPBF 25 is thrilled to extend our partnership for a second year in a row as the Official Broadcast Station of the U.S. Polo Assn. Palm Beaches Marathon, reaffirming our commitment to help bring such a unique and exciting event like this to our community," said President and General Manager, Caroline Taplett. "Working together with our incredible partners, Ken Kennerly and the Marathon team, we are dedicated to promoting a more connected community, supporting local businesses, and inspiring participants, locally, nationally, and internationally to join us in beautiful South Florida for this one-of-a-kind experience."About U.S. Polo Assn.U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.About The U.S. Polo Assn. Palm Beaches MarathonThe U.S. Polo Assn. Palm Beaches Marathon is a premier winter running event held annually in West Palm Beach, which features a range of race distances designed for runners of all abilities, including a full marathon, half marathon, 10K, 5K, and a 4-person marathon relay. Highlighted by a 100% flat, USATF-certified course, the Marathon serves as a Boston Marathon qualifier. The scenic route allows runners to experience West Palm Beach's vibrant downtown as it winds along palm-lined Flagler Drive, past historic neighborhoods, and features sparkling waterfront views. The event also supports community and charity efforts. Visit palmbeachmarathon.com.Contact InformationStacey KovalskyU.S. Polo Assn.skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul Narro Communications E: farah@narrocomms.com Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

聖地亞哥, 2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 由美國通用原子航空系統公司（General Atomics Aeronautical Systems, Inc., GA-ASI）設計與研製的 YFQ-42A 協同作戰飛機（Collaborative Combat Aircraft, CCA），目前正與美國空軍協同進行飛行測試。 這項歷史性成就延續了該公司快速打造新一代噴射動力無人平台的腳步。這些平台由美國空軍（USAF）主導，旨在確保制空優勢，同時在設計上兼顧快速量產、大規模生產以及合理成本。GA-ASI 總裁 David R. Alexander 表示：「對美國空軍與 GA-ASI 而言，這是多麼重要的時刻！正因為彼此的合作，我們才能在僅僅一年多的時間內完成 YFQ-42A 的建造與首飛。這是驚人的成就，我要向空軍的遠見致敬，也要向我們的開發團隊致敬，因為他們再一次為公司締造了歷史性的首次突破。」YFQ-42A 是 GA-ASI 最新的無人噴射機，專注於空對空半自主作戰任務，並以 XQ-67A「離機感測站」（Off-Board Sensing Station, OBSS）所首創的「屬級-種級」（genus-species）概念為基礎。藉由先進的模型導向數位工程（model-based digital engineering），GA-ASI 不僅加速了研發時程，還最佳化了制空能力。YFQ-42 的自主核心，已透過 GA-ASI 獨家擁有的噴射動力 MQ-20 Avenger® 進行超過五年的飛行測試訓練。這種隱身性、專注於空對空的無人噴射機，加上經過學習的 AI 自主核心，將為未來戰場上的作戰人員提供決定性的優勢。GA-ASI 的計畫重點在於建立一個高產能的生產環境，使美國空軍能夠在加速時程下達成生產超過 1,000 架 CCA 的目標。YFQ-42A 的地面測試已於今年 5 月展開。美國空軍於 2024 年 4 月選定 GA-ASI 負責建造並試飛一架完全符合量產規格的協同作戰飛機（CCA）。同年 3 月，美國空軍將該機命名為 YFQ-42A，其中「Y」表示為量產代表機（進入量產後「Y」字將被移除）、「F」代表戰鬥機（Fighter）、「Q」則代表無人飛機（Uncrewed）。GA-ASI 至今已研製出二十多種不同型號的無人飛機，並已交付超過 1,200 架給各類客戶。該公司位於加州波威市（Poway, Calif.）的五百萬平方英尺製造工廠，每年生產超過 100 架飛機。GA-ASI 的飛機總飛行時數已接近九百萬小時；全球每天每分鐘都有超過 50 架 GA-ASI 飛機在空中執行任務。關於 GA-ASI通用原子航空系統公司（GA-ASI）是通用原子公司的子公司，致力於設計與製造成熟可靠的遠程駕駛航空系統（RPA）、雷達與電光及相關任務系統，包括 Predator® RPA 系列與 Lynx® 多模式雷達。GA-ASI 累積飛行時數超過 900 萬小時，提供具備長航時與任務能力的航空平台，並整合感測器與數據鏈系統，以實現持續態勢感知。公司亦研發多種感測器控制與圖像分析軟體，提供飛行員訓練與支援服務，並開發超材料天線。更多資訊請參閱：www.ga-asi.com 。Avenger、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 均為通用原子航空系統公司在美國及其他國家/地區註冊的商標。聯絡資訊GA-ASI 媒體聯絡asi-mediarelations@ga-asi.com(858) 524-8101來源：通用原子航空系統公司 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - The YFQ-42A Collaborative Combat Aircraft, designed and developed by General Atomics Aeronautical Systems, Inc. (GA-ASI), is now conducting flight testing in coordination with the U.S. Air Force. This historic achievement continues the company's rapid creation of new, jet-powered uncrewed platforms chartered by the U.S. Air Force (USAF) to achieve air dominance while being designed for rapid production, in large quantities, at an affordable price."What a great moment for the U.S. Air Force and for GA-ASI," said GA-ASI President David R. Alexander. "It's been our collaboration that enabled us to build and fly the YFQ-42A in just over a year. It's an incredible achievement and I salute the Air Force for its vision and I salute our development team for delivering yet another historic first for our company."The YFQ-42A is GA-ASI's newest uncrewed jet, focused on air-to-air semi-autonomous operation and based on the genus-species concept pioneered on the XQ-67A Off-Board Sensing Station (OBSS). Using state-of-the-art, model-based digital engineering, GA-ASI was able to accelerate its schedule while optimizing air dominance capabilities. YFQ-42's autonomy core has been trained across more than five years of flight testing using GA-ASI's jet-powered MQ-20 Avenger®, an aircraft no other company has. The integrated capabilities of a stealthy, air-to-air-focused uncrewed jet, combined with a learned AI autonomy core, provide warfighters with a definitive advantage in the future fight.The GA-ASI program has focused on creating a high-rate production environment that enables USAF to reach its goal of producing more than 1,000 CCAs on an accelerated timeline. Ground testing for YFQ-42A began in May.USAF selected GA-ASI in April 2024 to build and fly a fully production-representative Collaborative Combat Aircraft (CCA). In March, USAF designated the aircraft the YFQ-42A, with the "Y" indicating a production-representative aircraft ("Y" will be dropped upon entering production), "F" signifying a fighter aircraft, and "Q" denoting an uncrewed aircraft.GA-ASI has developed more than two dozen different types of uncrewed aircraft and delivered more than 1,200 units to customers, building more than 100 aircraft per year at its 5 million-square-foot manufacturing facility in Poway, Calif. GA-ASI aircraft have amassed nearly 9 million total flight hours; more than 50 GA-ASI aircraft are aloft around the world every minute of every day.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging nearly 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc. registered in the United States and/or other countries.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，中創新航科技集團股份有限公司（「中創新航」或「公司」，股票代碼：3931.HK），公佈截至2025年6月30日止六個月（「報告期」）的未經審計簡明合併中期業績。報告顯示，上半年公司經營表現亮眼，實現營業收入人民幣16,418.88百萬元，較上年同期顯著增長31.7%；期內利潤實現人民幣752.99百萬元，同比大幅增長80.4%，在全球可再生能源發展加速轉型的態勢中展現出強勁的盈利能力與發展韌性。根據權威機構SNE Research統計，中創新航2025年上半年全球動力電池裝車量同比增長22.7%，排名穩居國內第三、全球第四，單月裝車量已達4.7GWh。在國內乘用車市場，公司表現尤為突出，6月、7月市占率連續創下新高，分別達到7.4%和8.25%。儲能領域增速更為迅猛，InfoLink資料顯示，公司上半年儲能電芯出貨量躍升至全球前四，實現里程碑式發展。支撐這一系列成績的，是中創新航技術的持續突破和多款重磅產品的量產落地。上半年，中創新航攜「頂流」電池持續引領技術前沿，公司400Wh/kg固液混合電池產品即將量產配套，全固態電池研發取得突破、生產線貫通投用。此外，公司高功率磷酸鐵鋰R46大圓柱電池實現行業內首家量產配套，成功助力吉利、東風最新混動車型；而下一代210Wh/kg以上能量密度磷酸錳鐵鋰電池產品也即將批量應用，該產品可實現10%電量至80%電量充電時間15分鐘，產品性能進一步提升。在乘用車市場，憑藉卓越的產品實力，中創新航成功實現大眾、現代、豐田全球前三大車企集團全部進入。上半年，其800V 5C電池實現月銷量超2萬台，順利推進配套小鵬、樂道、零跑、奧迪、北汽等多個車型，該超充電池三元版本獨家配套全新小鵬P7，並助力其創下24小時行駛3971公里的全球紀錄。在商用車領域，中創新航構建至遠電池全場景、全覆蓋、全賦能的產品矩陣架構，上半年國內商用車裝車量同比增長310%。公司行業首推輕卡車型百萬公里定製版，大幅提升電池系統質保，獲得業內廣泛認可，目前已與奇瑞、吉利、瑞馳、福田、東風、長安、金龍等知名企業深度合作。在重商領域，公司以場景化電量設計深耕市場，與重汽、徐工、三一、陝汽、解放、東風、臨工、柳工等客戶在多方面達成全方位合作。伴隨著國際市場的重大突破，中創新航上半年儲能業務發展迅猛。其314Ah二代長迴圈儲能電芯憑藉96%以上的能效、15,000次的超長壽命、前1,000次迴圈零衰減的卓越性能獲得國內國際客戶的高度認可，並成功斬獲拉美和南非最大電站專案，進入多家頭部開發商和電網公司的供應商名錄。另外，公司新一代「至久」588Ah、600Ah+儲能大電芯亦將於今年量產。除此之外，作為行業首家通過eVTOL動力電池製造符合性審查的企業，中創新航大力探索新興市場，助力我國低空經濟發展。目前，公司310Wh/kg的R46圓柱電芯已量產配套行業頭部eVTOL企業。同時，中創新航已與廣汽高域簽署深化戰略合作協定，約定在eVTOL領域展開深入合作，共同推進eVTOL電源標準化產品的發展。整體來看，中創新航上半年圍繞「產品與技術領先」戰略，加速全球化產能佈局。目前，泰國Pack工廠已穩定交付，且葡萄牙基地也已於2025年一季度破土動工，未來隨著其產業鏈佈局的進一步完善，中創新航有望憑藉跨領域、跨場景的動儲產品矩陣，實現動儲業務深度協同，全場景打造硬核產品力，同時，持續開拓軌道交通、礦山礦用、低空飛行、人形機器人等新興市場，持續推進「能源+」戰略落地，進一步推進在全球新能源產業中的領先地位。關於中創新航集團有限公司中創新航（3931.HK）是專業從事鋰電池、電池管理系統及相關整合式產品和鋰電池材料的研製、生產、銷售和市場應用開發的新能源高科技企業。作為電池專家，公司致力於構建全方位能源運營體系，為以動力及儲能為代表的新能源全場景應用市場提供完善的產品解決方案和全生命週期管理。目前，公司已建立江蘇、福建、四川、湖北、安徽、廣東等多個產業基地，完成全方位國內產業佈局，同時已設立歐洲產業基地、泰國產業基地，大力拓展海外產業佈局，打造擁有規模化智慧製造實力的國際化領先企業。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com